TABLE 5.
Multivariable Logistic Regression Results Predicting High Adherencea
| PDC ≥ 0.80 to Index NOAC | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 3 Months | 6 Months | 9 Months | |||||||
| OR | 95% CL | OR | 95% CL | OR | 95% CL | ||||
| Index medication | |||||||||
| Dabigatran vs. rivaroxaban | 0.67 | 0.61 | 0.73 | 0.66 | 0.60 | 0.72 | 0.70 | 0.63 | 0.77 |
| Apixaban vs. rivaroxaban | 0.87 | 0.79 | 0.96 | 0.87 | 0.79 | 0.96 | 0.86 | 0.77 | 0.96 |
| Dabigatran vs. apixabanb | 0.76 | 0.68 | 0.86 | 0.75 | 0.67 | 0.84 | 0.81 | 0.71 | 0.93 |
| Demographic and clinical characteristics | |||||||||
| Aged 65-74 years vs. < 65 years | 2.60 | 2.36 | 2.85 | 3.11 | 2.83 | 3.42 | 4.69 | 4.22 | 5.21 |
| Aged ≥ 75 years vs. < 65 years | 2.47 | 2.25 | 2.71 | 3.06 | 2.79 | 3.36 | 4.79 | 4.32 | 5.32 |
| Hypertension | 1.20 | 1.11 | 1.30 | 1.18 | 1.10 | 1.28 | 1.19 | 1.09 | 1.29 |
| Diabetes | 1.24 | 1.11 | 1.38 | 1.30 | 1.17 | 1.45 | 1.29 | 1.15 | 1.45 |
| Charlson Comorbidity Index | 0.92 | 0.88 | 0.96 | 0.91 | 0.87 | 0.95 | 0.92 | 0.88 | 0.96 |
| Hyperlipidemia | 1.16 | 1.07 | 1.25 | 1.04 | 0.97 | 1.12 | 1.04 | 0.96 | 1.12 |
| Cancer | 1.24 | 1.09 | 1.42 | 1.22 | 1.07 | 1.39 | 1.20 | 1.05 | 1.39 |
| PDC ≥ 0.80 to All OACs | |||||||||
| 3 Months | 6 Months | 9 Months | |||||||
| OR | 95% CL | OR | 95% CL | OR | 95% CL | ||||
| Index medication | |||||||||
| Dabigatran vs. rivaroxaban | 0.82 | 0.74 | 0.90 | 0.84 | 0.76 | 0.92 | 0.90 | 0.82 | 1.00 |
| Apixaban vs. rivaroxaban | 0.92 | 0.91 | 0.93 | 0.88 | 0.80 | 0.97 | 0.86 | 0.78 | 0.96 |
| Dabigatran vs. apixabanb | 0.92 | 0.82 | 1.04 | 0.95 | 0.84 | 1.07 | 1.05 | 0.92 | 1.19 |
| Demographic and clinical characteristics | |||||||||
| Aged 65-74 years vs. < 65 years | 2.94 | 2.66 | 3.24 | 3.60 | 3.27 | 3.97 | 5.43 | 4.89 | 6.04 |
| Aged ≥ 75 years vs. < 65 years | 2.70 | 2.45 | 2.97 | 3.40 | 3.09 | 3.74 | 5.28 | 4.76 | 5.85 |
| Hypertension | 1.23 | 1.14 | 1.33 | 1.23 | 1.13 | 1.33 | 1.14 | 1.35 | 1.14 |
| Diabetes | 1.24 | 1.11 | 1.39 | 1.27 | 1.14 | 1.42 | 1.13 | 1.43 | 1.13 |
| Charlson Comorbidity Index | 0.92 | 0.87 | 0.96 | 0.91 | 0.87 | 0.95 | 0.92 | 0.87 | 0.96 |
| Hyperlipidemia | 1.21 | 1.12 | 1.31 | 1.06 | 1.06 | 1.15 | 1.02 | 0.94 | 1.11 |
| Cancer | 1.28 | 1.12 | 1.48 | 1.16 | 1.02 | 1.33 | 1.19 | 1.03 | 1.37 |
Note: The full cohort was included in each model with no missing variables for any subjects. Other variables included in the model with nonsignificant effects: gender, urban/rural status, region, history of stroke, vascular disease, renal disease, liver disease, prior bleeding or medications that increase risk of bleeding, alcohol abuse, and dementia. CHA2DS2-VASc and HAS-BLED scores were expanded to individual variables rather than summarized scores.
aHigh adherence = PDC ≥ 0.80.
bAttained using the same model and changing the reference treatment group to apixaban.
CL = confidence limit; NOAC = non-vitamin K oral anticoagulant; OAC = oral anticoagulant; OR = odds ratio; PDC = proportion of days covered.